InTechOpen uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Biochemistry, Genetics and Molecular Biology » "Mesenchymal Stem Cells - Isolation, Characterization and Applications", book edited by Phuc Van Pham, ISBN 978-953-51-3616-3, Print ISBN 978-953-51-3615-6, Published: November 29, 2017 under CC BY 3.0 license. © The Author(s).

Chapter 13

Transportation of Mesenchymal Stem Cells for Clinical Applications

By Tomoki Aoyama
DOI: 10.5772/67716

Article top


The scenarios of MSC transportation. (A) Extraction of materials in a hospital. (B) Extracted materials are transported to a cell‐processing centre, and MSC products are transported to the hospital. (C) In some cases, MSCs are stored in a cell bank.
Figure 1. The scenarios of MSC transportation. (A) Extraction of materials in a hospital. (B) Extracted materials are transported to a cell‐processing centre, and MSC products are transported to the hospital. (C) In some cases, MSCs are stored in a cell bank.
A three‐level packaging system of a transportation box in regenerative medicine.
Figure 2. A three‐level packaging system of a transportation box in regenerative medicine.
The cell number of MSCs peeled from a culture dish and incubated at 4, 20, or 37°C in a culture medium for 24 h. Living cell and dead cell numbers were determined by means of the Live/Dead Staining Kit II (Takara Bio Inc., Shiga, Japan).
Figure 3. The cell number of MSCs peeled from a culture dish and incubated at 4, 20, or 37°C in a culture medium for 24 h. Living cell and dead cell numbers were determined by means of the Live/Dead Staining Kit II (Takara Bio Inc., Shiga, Japan).

Transportation of Mesenchymal Stem Cells for Clinical Applications

Tomoki Aoyama
Show details


Cell‐processing procedures are conducted in accordance with Good Manufacturing Practices, and clinical procedures are performed by highly optimised methods. A high‐quality transportation system is essential for safe and effective handling of mesenchymal stem cells (MSCs) between cell‐processing and transplantation stages. For MSC transportation, either frozen cell or non‐frozen cell transportation is performed. There are many requirements for transporting a package by either type of transportation. In frozen cell transportation, some issues have yet to be resolved: the primary receptacle and cryoprotectant reagents. In non‐frozen cell transportation, control of cell metabolism and protection from environmental changes are more serious problems. Stabilisation of temperature, shock resistance, gas control, and an ultraviolet radiation (UVR) shielding technology should be considered. The transportation system should be established in compliance with the guidelines. Both development of a high‐quality transportation package and establishment of a high‐quality transportation system are important for the effective use of MSCs in clinical applications.

Keywords: transport, mesenchymal stem cell, regenerative medicine, clinical use

1. Introduction

Cell‐processing procedures are conducted in accordance with Good Manufacturing Practices, and clinical procedures such as transplantation and infusion are performed using highly optimised techniques [1]. Thus, a high‐quality transportation system is necessary for safe and effective handling of materials and mesenchymal stem cell (MSC) products between cell‐processing and transplantation stages. Frozen cell transportation is conventionally used in laboratories. Nonetheless, there may be some disadvantages of this method for clinical applications. For example, the tubes usually used for frozen transportation are not completely sealed receptacles, and the cryoprotection reagents have some effects on the human body. In non‐frozen cell transportation, control of cell metabolism and protection from environmental changes are serious problems. A transportation system should be established to prevent man‐made incidents. In this study, the elements required for transportation of MSCs are discussed.

2. Conditions required for MSC transportation

There are many possible scenarios of MSC transportation. When the MSCs are isolated immediately from materials in a hospital, establishment of a transportation system inside the hospital is needed (Figure 1A). If further manipulation of MSCs or mass culture is performed, MSC materials such as bone marrow, cord blood, and adipose tissue are transported from the hospital to a cell‐processing centre (CPC). At a CPC, the materials are cultured and manipulated and then transported to the hospital (Figure 1B). These transportation scenarios (Figure 1A, B) work effectively with autogenic transplantation. When allogeneic transplantation is performed, some temporary storage is used. In such cases, other facilities such as cell banks or stock houses are added [2] (Figure 1C).


Figure 1.

The scenarios of MSC transportation. (A) Extraction of materials in a hospital. (B) Extracted materials are transported to a cell‐processing centre, and MSC products are transported to the hospital. (C) In some cases, MSCs are stored in a cell bank.

Basically, when the transportation is performed within a hospital, there are not many requirements for the transportation package and transport system if a good environment is maintained in the hospital. Some packaging technology is needed when outside transportation is performed among a hospital, CPC, and cell bank (Figure 1B, C). In the outside environment, the transported materials and MSC products should be protected from some external environmental factors such as micro‐organisms, temperature, shocks, humidity, ultraviolet radiation (UVR), and atmospheric pressure. The transportation package should withstand such external environmental stimuli.

3. Requirements for transportation and three‐level packaging

There are some requirements for transportation of MSCs for clinical use:

  • Leakproofness

  • Sterility

  • Temperature stabilisation

  • Shock resistance

  • Gas stability

  • UV shielding

  • Monitoring

Each requirement is important, but the degree of importance is different in each transportation scenario (Figure 1, Table 1). A single type of package cannot fulfil all the requirements. A three‐level packaging system is recommended by the World Health Organisation (WHO) [3] (Figure 2). Each package satisfies each requirement. Tests required for compliance with the criteria include a 9‐m drop test, a puncture test, and a stacking test for the packages [3].


Figure 2.

A three‐level packaging system of a transportation box in regenerative medicine.

SterilityShock resistanceTemperature stabilisationMonitoring
Inside hospital✓✓
From hospital to CPC (materials)✓✓✓✓✓✓✓✓
From CPC to hospital (products)
From cell bank to hospital (products)
From stockhouse to hospital (products)

Table 1.

Technologies needed for each processing scenario of MSC materials and products.

MSC, mesenchymal stromal cell; CPC, cell‐processing centre.

3.1. The primary receptacle

The materials and the cell products are inserted into the first package. The primary receptacle should be completely sealed to prevent invasion of micro‐organisms and leakage of contents. The materials constituting the primary receptacle should be chosen carefully to prevent elution of chemical materials. Packaging the contents into the primary receptacle is performed in the CPC area, and the primary receptacle should be sterilised.

3.2. The second package

The primary receptacle is inserted into the second package (Figure 2). Sterilisation treatment of the second package is not necessary if the complete sterilisation and sealing are achieved for the primary receptacle. Some materials for absorbing liquids are needed if the first receptacle is broken and the contents leak out. A shock absorber and temperature control system such as materials for hot storage are included in the second package. For monitoring the temperature and shocks, a sensing device is also included.

3.3. The outer package

The second package is placed into the outer package (Figure 2). The outer level is the packaging most exposed to external environmental stimuli. The characteristics of heat insulation, toughness, waterproofness, and UV shielding are necessary. For the handling, slings and belts are attached to the outer package. A notice, security lock, and invoice are attached as acquired.

4. Requirements for the packages

4.1. Leakproofness

Tight sealing is required from the standpoint of leakproofness and sterility. According to the ‘Guidance on Regulations for the Transport of Infectious Substances’, leakproofness is required in the primary receptacle and second package [3]. The guidance itself is used for transportation of ‘infectious substances’, but it defines the ‘patient specimens’ and ‘biological products’ as ‘infectious substances’. Thus, this guidance is to be used as a reference. If the primary receptacle loses leakproofness and springs a leak, some absorbent materials in the second package should absorb all fluid [3]. Whatever the intended temperature of the consignment, the primary receptacle and secondary package should withstand (without leakage) the internal pressure no less than 95 kPa in the range of temperatures from -40 to +55°C [3].

4.2. Sterility

The importance of sterility does not need to be explained. To guarantee sterility, the primary receptacle should be completely sealed. Therefore, the semi‐closed cap‐type receptacle typically used for frozen transportation is not recommended as a primary receptacle. Besides, the primary receptacle itself should be sterilised.

4.3. Temperature stabilisation

Stabilisation of temperature is employed to control cell metabolism and to prevent degradation of cells and products. There are two categories for temperature stabilisation: frozen cell or non‐frozen cell transportation.

In the field of frozen cell transportation, research and development on the freezing procedure are conducted for the purpose of storage. The success of frozen cell transportation and storage depends on the temperature control and cryoprotective agents [4]. According to Hubel, understanding the mobility of water is paramount for good insight into biochemical reactions during freezing [4]. The temperature dependence of protein activity obeys the Arrhenius equation [4, 5]:


where k is the rate constant, T is the absolute temperature (Kelvins), A is the pre‐exponential factor, Ea is the activity energy for the reaction (Joules), and R is the universal gas constant. The optimal temperature for transportation and storage should be selected below the threshold temperature to manage activity of a protein [4]. Distinct changes are observed near -53°C [6, 7]. A substrate fails to bind to ribonuclease A at -58°C [8]. Some authors reported that activity of β‐glucosidase is observed even at -70°C [9, 10]. These results suggest that a trace protein activity may persist even at a low temperature, below -80°C [4]. To stabilise proteins and minimise cell dehydration, pharmaceutical agents are used for cryoprotection. Cryoprotectants are classified into permeating and non‐permeating agents depending on their ability to cross the cell membrane [11, 12]. The permeating cryoprotectants, such as dimethyl sulphoxide (DMSO), are used for clinical preservation and banking of MSCs for the treatment of graft‐versus‐host disease (GVHD) [13]. The International Stem Cell Initiative (ISCI) recommends the use of dry shippers involving liquid nitrogen (-196°C) for frozen stem cell transportation [2]. Nonetheless, some issues should be resolved regarding cryopreservation and frozen cell transportation. A significant loss of living cells after recovery occurs after cryopreservation. The proportion of apoptotic and senescent cells increases during cryopreservation in comparison with fresh live culture [1416]. Not only cell viability but also alteration of MSC characteristics is to be considered. Immunosuppressive properties of MSCs are altered after cryopreservation although these alterations may be favourable for the treatment of GVHD [17, 18]. DMSO is the most widely used cryoprotectant in the world, but it has some adverse effects on patients such as nausea, headache, hypotension, hypertension, and diarrhoea [19]. Further research and development on cryoprotectants, freezing and thawing technologies, cell containers, the primary receptacle, and administration method are needed for frozen cell transportation.

In non‐frozen cell transportation, control of cell metabolism is compromised. There is little information about the non‐frozen cell transportation of MSCs. Information on the storage of platelets serves as a useful reference. Platelets are stored between 20 and 24°C with continuous agitation, suspended in plasma with a citrate‐based anticoagulant [20]. Platelets at 4°C undergo a shape change, α‐granule release, aggregation, apoptosis, and a significant reduction of the lifespan. When MSCs that are detached from a culture dish are incubated at 4, 20, or 37°C in a culture medium for 24 h, the living cell numbers after 37°C incubation are higher. Nevertheless, dead cell numbers increase after 37°C incubation (Figure 3). This result shows that cell metabolism is not sufficiently controlled during 37°C incubation. The development of a preservation solution and verification of suitable temperature are necessary for non‐frozen‐MSC transportation.


Figure 3.

The cell number of MSCs peeled from a culture dish and incubated at 4, 20, or 37°C in a culture medium for 24 h. Living cell and dead cell numbers were determined by means of the Live/Dead Staining Kit II (Takara Bio Inc., Shiga, Japan).

4.4. Shock and vibration resistance

There is little or no information about the bioresponse of MSCs to shocks and vibration during transportation. One study evaluated the shocks and vibration associated with truck and railway transportation [21]. Peak shock acceleration for the longitudinal axis was 2.8g, for the transverse axis 2.3g, and for vertical axis 7.0g on a truck, and all axes were 4.7g on a train when a 22‐ton cargo was transported [22]. Peak vibration acceleration for the longitudinal axis was 0.27g; for the transverse axis, it was 0.27g; and for the vertical axis, 0.52g on a truck. The frequency range was 0–1900 Hz [22]. Peak vibration acceleration for the longitudinal axis was 0.10g, transverse axis 0.19g, and vertical axis 0.52g on a train. The frequency range was 0–750 Hz [23]. Strong shocks should be prevented from destroying the extracellular matrix of products. Microvibration should be considered for prevention of changes in the characteristics of MSCs. The lipid membrane, primary cilium, extracellular matrix, and intracellular cytoskeleton respond to mechanical stimuli. They transduce mechanical stimuli via ion channels, integrins, and focal adhesion kinase and thus alter gene expression and protein synthesis. As a consequence, survival, apoptosis, proliferation, and differentiation properties are affected [24]. For example, MSCs were stimulated by vibration from 1 to 1000 Hz, and myogenic transcription factors were found to be upregulated by low frequencies (1 and 50 Hz), but osteogenic transcription factors were upregulated by high frequencies (500 and 1000 Hz) [25]. These data suggest that some shock absorber is needed to prevent the shocks and vibration.

4.5. Gas stability

In frozen-MSC transportation, gas control is not needed, but in non-frozen-MSC transportation, some gas control technology is necessary. When we consider the gas control, the knowledge about cellular senescence is crucial. Cellular senescence was discovered in the 1960s by Hayflick [26]. He showed that human diploid fibroblasts have a limited ability to proliferate; it is called senescence in ex vivo culture [26]. Some stressors, such as dysfunctional telomeres, genotoxic stressors, DNA damage, UVR, and oxidative stress, induce cellular senescence [27]. This phenomenon is induced by the upregulation of p16INK4A in MSCs [28]. The expression of p16INK4A is associated with oxidative stress. When MSCs are cultured under hypoxic conditions (1% pO2), their proliferation is increased by 8–20 population doublings as compared with normoxic conditions (20% pO2) [29]. The p16INK4A gene is downregulated in hypoxic culture [29]. An antioxidant agent that induces 5% pO2 conditions [30] and 3% hydrogen gas treatment [31] prolongs the replicative lifespan. Not only cellular proliferation but also the characteristics of MSCs are influenced by gas conditions. The osteogenic differentiation potential is not influenced, but adipogenic and chondrogenic differentiation abilities are enhanced under hypoxic culture conditions [29]. Cell surface antigens are downregulated, and the ability to suppress T‐cell proliferation is diminished by oxidative stress [32]. These results suggest that some gas control system is required for non‐frozen‐MSC transportation.

4.6. UVR shielding

UVR is a natural component of sunlight and is invisible to the human eye. There are three types of UVR by wavelength: UV‐A (315–400 nm), UV‐B (280–315 nm), and UV‐C (100–280 nm). UV‐A and UV‐B can reach the Earth's surface, but the ozone layer filters out UV‐C [33]. Ageing of skin associated with UVR exposure is referred to as photoageing. Sun‐exposed areas of the skin, such as the face and neck, undergo premature ageing [33]. UV‐A induces production of reactive oxygen species (ROS) and activates cell cycle checkpoint proteins such as p53 and p21 [34]. UV‐B exposure causes structural rearrangement of nucleotides that leads to defects in DNA strands. The UVR‐induced ROS production and DNA damage to epidermal stem cells lead to photoageing [33]. Although there are many reports about the harmful effects of UVR on epidermal stem cells, there is little information about UVR effects on MSCs. The report on the gene expression profile, when MSCs were exposed to low‐dose UV‐B, showed that only a minimal change in gene expression was induced [35]. Further research is needed and some UVR shielding technology may be required, especially in case of air transportation.

4.7. Monitoring

Temperature data loggers are required for proof that transportation was completed without a problem. In the absence of temperature data loggers, consideration should be given to the use of chemical or other indicators to provide information on temperature during transportation [2]. If the shock resistance, gas control, and UV shielding are crucial for the transportation of MSCs, then acceleration sensors, gas monitoring, and radiation monitoring should be considered.

5. Transportation systems

Establishment of a transportation system is required in compliance with the government regulations in each country and international guidelines. At present, there is no specific guidance on transportation for regenerative medicine. Nonetheless, some guidelines issued by the ISCI [2] and WHO [3] and specific legislation in Europe [36] can be used for reference.

Education of delivery personnel to prevent man‐made incidents, preparation of the documentation for clearance, a traceability system, and security control should be provided. Further research and consensus guidelines are needed for the transportation of materials related to MSCs and cell products for clinical use.


This work was supported by JSPS KAKENHI grant number 26282154. The author acknowledges members of the BioL Foundation.



Mesenchymal stem cell


Good Manufacturing Practices


Cell‐processing centre


Graft‐versus‐host disease


Dimethyl sulfoxide


Cyclin‐dependent kinase 4 inhibitor p16


Deoxyribonucleic acid


Ultraviolet radiation


Reactive oxygen species


1 - Codinach M, Blanco M, Ortega I, Lloret M, Reales L, Coca MI, Torrents S, Doral M, Oliver‐Vila I, Requena‐Montero M, Vives J, Garcia‐López J. Design and validation of a consistent and reproducible manufacture process for the production of clinical‐grade bone marrow‐derived multipotent mesenchymal stromal cells. Cytotherapy. 2016;18:1197-1208. doi:10.1016/j.jcyt.2016.05.012
2 - Andrews PW, Baker D, Benvinisty N, Miranda B, Bruce K, Brüstle O, Choi M, Choi YM, Crook JM, de Sousa PA, Dvorak P, Freund C, Firpo M, Furue MK, Gokhale P, Ha HY, Han E, Haupt S, Healy L, Hei DJ, Hovatta O, Hunt C, Hwang SM, Inamdar MS, Isasi RM, Jaconi M, Jekerle V, Kamthorn P, Kibbey MC, Knezevic I, Knowles BB, Koo SK, Laabi Y, Leopoldo L, Liu P, Lomax GP, Loring JF, Ludwig TE, Montgomery K, Mummery C, Nagy A, Nakamura Y, Nakatsuji N, Oh S, Oh SK, Otonkoski T, Pera M, Peschanski M, Pranke P, Rajala KM, Rao M, Ruttachuk R, Reubinoff B, Ricco L, Rooke H, Sipp D, Stacey GN, Suemori H, Takahashi TA, Takada K, Talib S, Tannenbaum S, Yuan BZ, Zeng F, Zhou Q. Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regenerative Medicine. 2015;10(2 Suppl):1-44. doi:10.2217/rme.14.93
3 - World Health Organization. Guidance on regulations for the transport of infectious substances 2013-2014: applicable as from 1 January 2013.
4 - Hubel A, Spindler R, Skubitz AP. Storage of human biospecimens: selection of the optimal storage temperature. Biopreservation and Biobanking. 2014;12:165-175. doi:10.1089/bio.2013.0084
5 - Arrhenius S. On the reaction rate of the inversion of non‐refined sugar upon souring. Zeitschrift für Physikalische Chemie. 1889;4:226-248.
6 - Doster W, Cusack S, Petry W. Dynamical transition of myoglobin revealed by inelastic neutron scattering. Nature. 1989;337:754-756.
7 - Hartmann H, Parak F, Steigemann W, Petsko GA, Ponzi DR, Frauenfelder H. Conformational substates in a protein: structure and dynamics of metmyoglobin at 80 K. Proceedings of the National Academy of Sciences of the United States of America. 1982;79:4967-4971.
8 - Rasmussen BF, Stock AM, Ringe D, Petsko GA. Crystalline ribonuclease A loses function below the dynamical transition at 220 K. Nature. 1992;357:423-424.
9 - Bragger JM, Dunn RV, Daniel RM. Enzyme activity down to -100 degrees C. Biochimica et Biophysica Acta. 2000;1480:278-282.
10 - More N, Daniel RM, Petach HH. The effect of low temperatures on enzyme activity. Biochemistry Journal. 1995;305:17-20.
11 - Meryman HT. Cryoprotective agents. Cryobiology. 1971;8:173-183.
12 - Meryman HT. Cryopreservation of living cells: principles and practice. Transfusion. 2007;47:935-945.
13 - Marquez‐Curtis LA, Janowska‐Wieczorek A, McGann LE, Elliott JA. Mesenchymal stromal cells derived from various tissues: biological, clinical and cryopreservation aspects. Cryobiology. 2015;71:181-197. doi:10.1016/j.cryobiol.2015.07.003
14 - Chinnadurai R, Garcia MA, Sakurai Y, Lam WA, Kirk AD, Galipeau J, Copland IB. Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo. Stem Cell Reports. 2014;3:60-72. doi:10.1016/j.stemcr.2014.05.003
15 - Chinnadurai R, Copland IB, Garcia MA, Petersen CT, Lewis CN, Waller EK, Kirk AD, Galipeau J. Cryopreserved mesenchymal stromal cells are susceptible to T‐cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells. 2016;34:2429-2442. doi:10.1002/stem.2415
16 - Pollock K, Sumstad D, Kadidlo D, McKenna DH, Hubel A. Clinical mesenchymal stromal cell products undergo functional changes in response to freezing. Cytotherapy. 2015;17:38-45. doi:10.1016/j.jcyt.2014.06.008
17 - Holubova M, Lysak D, Vlas T, Vannucci L, Jindra P. Expanded cryopreserved mesenchymal stromal cells as an optimal source for graft‐versus‐host disease treatment. Biologicals. 2014;42:139-144. doi:10.1016/j.biologicals.2014.01.003
18 - François M, Copland IB, Yuan S, Romieu‐Mourez R, Waller EK, Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat‐shock response and impaired interferon‐γ licensing. Cytotherapy. 2012;14:147-152. doi:10.3109/14653249.2011.623691
19 - Alessandrino P, Bernasconi P, Caldera D, Colombo A, Bonfichi M, Malcovati L, Klersy C, Martinelli G, Maiocchi M, Pagnucco G, Varettoni M, Perotti C, Bernasconi C. Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 126 cases. Bone Marrow Transplantation. 1999;23:533-537.
20 - Capocelli KE, Dumont LJ. Novel platelet storage conditions: additive solutions, gas, and cold. Current Opinion in Hematology. 2014;21:491-496. doi:10.1097/MOH.0000000000000081
21 - Maheres SJ, Lahti EA, Ross SB. Used fuel disposition campaign storage and transportation. Transportation shock and vibration literature review. FCRD‐UFD‐2013‐000169. PNNL‐22514. 2013.
22 - Magnuson CF. Shock and vibration environments for large shipping container during track transport (Part I). SAND77‐1110. Sandia National Laboratories, Albuquerque, New Mexico. 1977.
23 - Magnuson CF. Shock and vibration environments during normal rail transportation of heavy cargo. SAND82‐0819. Sandia National Laboratories, Albuquerque, New Mexico. 1982.
24 - Liu YS, Lee OK. In search of the pivot point of mechanotransduction: mechanosensing of stem cells. Cell Transplantation. 2014;23:1-11. doi:10.3727/096368912X659925
25 - Childs PG, Boyle CA, Pemberton GD, Nikukar H, Curtis AS, Henriquez FL, Dalby MJ, Reid S. Use of nanoscale mechanical stimulation for control and manipulation of cell behaviour. Acta Biomaterialia. 2016;34:159-168. doi:10.1016/j.actbio.2015.11.045
26 - Hayflick L. The limited in vitro lifetime of human diploid cell strains. Experimental Cell Research. 1965;37:614-636.
27 - Turinetto V, Vitale E, Giachino C. Senescence in human mesenchymal stem cells: functional changes and implications in stem cell‐based therapy. International Journal of Molecular Sciences. 2016;17:pii: E1164. doi:10.3390/ijms17071164
28 - Shibata KR, Aoyama T, Shima Y, Fukiage K, Otsuka S, Furu M, Kohno Y, Ito K, Fujibayashi S, Neo M, Nakayama T, Nakamura T, Toguchida J. Expression of the p16INK4A gene is associated closely with senescence of human mesenchymal stem cells and is potentially silenced by DNA methylation during in vitro expansion. Stem Cells. 2007;25:2371-2382.
29 - Jin Y, Kato T, Furu M, Nasu A, Kajita Y, Mitsui H, Ueda M, Aoyama T, Nakayama T, Nakamura T, Toguchida J. Mesenchymal stem cells cultured under hypoxia escape from senescence via down‐regulation of p16 and extracellular signal regulated kinase. Biochemical and Biophysical Research Communications. 2010;391:1471-1476. doi:10.1016/j.bbrc.2009.12.096
30 - Ito A, Aoyama T, Yoshizawa M, Nagai M, Tajino J, Yamaguchi S, Iijima H, Zhang X, Kuroki H. The effects of short‐term hypoxia on human mesenchymal stem cell proliferation, viability and p16(INK4A) mRNA expression: investigation using a simple hypoxic culture system with a deoxidizing agent. Journal of Stem Cells and Regenerative Medicine. 2015;11:25-31.
31 - Kawasaki H, Guan J, Tamama K. Hydrogen gas treatment prolongs replicative lifespan of bone marrow multipotential stromal cells in vitro while preserving differentiation and paracrine potentials. Biochemical and Biophysical Research Communications. 2010;397:608-613. doi:10.1016/j.bbrc.2010.06.009
32 - Denu RA, Hematti P. Effects of oxidative stress on mesenchymal stem cell biology. Oxidative Medicine and Cellular Longevity. 2016;2016:2989076. doi:10.1155/2016/2989076
33 - Panich U, Sittithumcharee G, Rathviboon N, Jirawatnotai S. Ultraviolet radiation‐induced skin aging: the role of DNA damage and oxidative stress in epidermal stem cell damage mediated skin aging. Stem Cells International. 2016;2016:7370642. doi:10.1155/2016/7370642
34 - Peng Y, Xuan M, Leung VYL, Cheng B. Stem cells and aberrant signalling of molecular systems in skin aging. Ageing Research Reviews. 2015;19:8-21. doi:10.1016/j.arr.2014.10.006
35 - Wong DY, Ranganath T, Kasko AM. Low‐dose, long‐wave UV light does not affect gene expression of human mesenchymal stem cells. PLoS One. 2015;10:e0139307. doi:10.1371/journal.pone.0139307
36 - Beck G, Schenerman M, Dougherrty J, Cordoba‐Rodriguez R, Joneckis C, Mire‐Sluis A, McLeod LD. Raw material control strategies for bioprocesses. Bioprocess International. 2009;9:18-33.